Quick Answer
Senti Biosciences Holdings, Inc. reported Research And Development Expense of $37.59 million for the year ending 2025.
- Senti Biosciences Holdings, Inc. showed an increase of +9.4% in Research And Development Expense from 2024 to 2025.
- This data is from Senti Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $5.24 million | Q3 2021: $5.41 million | Q1 2022: $7.60 million | Q2 2022: $9.25 million | Q3 2022: $6.52 million | Q1 2023: $7.06 million | Q2 2023: $6.88 million | Q3 2023: $9.09 million | Q1 2024: $8.78 million | Q2 2024: $9.15 million | Q3 2024: $8.66 million | Q1 2025: $9.28 million | Q2 2025: $10.03 million | Q3 2025: $10.52 million.
- Over the full 5 years of available data (2021 to 2025), Senti Biosciences Holdings, Inc.'s Research And Development Expense has grown by 71.2%.
- Historical annual values: Fiscal year 2025: $37.59 million | Fiscal year 2024: $34.36 million | Fiscal year 2023: $32.15 million | Fiscal year 2022: $28.15 million | Fiscal year 2021: $21.96 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: